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Abstract
We performed an 11-year retrospective analysis of consecutive nonduplicate methicillin-resistant Staphylococcus aureus (MRSA) clinical
isolates in two neighbouring hospitals in the Paris area. MRSA isolates were classiﬁed according to resistance (R) to ﬂuoroquinolones
(Fq), kanamycin (K), tobramycin (T) and gentamicin (G). The yearly number of MRSA isolates (3446 in total) decreased, from approxi-
mately 350 in 1997–2002 to 212 in 2007. Four patterns (P) were found: P1 (KTGFq R, n = 776), P2 [KTFq R; G susceptible (S),
n = 1630], P3 (Fq R; KTG S, n = 397) and P4 (Fq S; any KTG susceptibility, n = 201). P1 predominated in 1997 (183 isolates) then
dropped sharply (nine in 2007); P2 and P4 remained stable over time; and P3 increased from 13 isolates in 1997 to 72 in 2007. Pat-
terns were signiﬁcantly and positively associated with several variables, independently of the year of collection: P1, age < 80 years,
male gender, intensive care unit stay, and hospital onset; P3, age > 80 years and stay in intermediate or long-term care wards; and P4,
age < 40 years, stay in an obstetric ward, and imported cases. Molecular typing of 79 isolates in 2005 and 2007 using multilocus
sequence typing, spa type, and SCCmec showed that P1, P2 and P3 isolates were mainly clonal, whereas P4 isolates were more
diverse. P1 comprised mainly ST247-I isolates, P2 mainly ST8-IVc, and P3 mainly ST8-IVc and ST5-VI. In conclusion, the epidemiology
of MRSA in Paris is changing rapidly at the local level, with phenotypically deﬁned clones being substituted by others, with associations
existing between changes in speciﬁc patient populations or circumstances.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is endemic
in healthcare facilities in most countries throughout the
world [1]. The epidemiology of MRSA is evolving rapidly,
with emerging or reemerging clones replacing older ones.
Several healthcare-associated clones appeared and spread in
the 1980s [1]. More recently, community-associated MRSA
clones have emerged, adding to the complexity of the epide-
miological situation [2].
In France, gentamicin-susceptible MRSA clones emerged in
hospitals in the early 1990s and gradually replaced gentami-
cin-resistant ones [3,4]. We recently noted the increasing
susceptibility of MRSA isolates to antibiotics other than gen-
tamicin in our hospital. We therefore conducted a retro-
spective 11-year epidemiological study of patients with
MRSAs and analysed, for selected strains, their genetic back-
ground, according to deﬁned susceptibility patterns.
Materials and Methods
Hospital setting
We analysed MRSA data from a microbiology laboratory that
handled specimens from two hospitals located near to each
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other in Paris, France. The Bichat–Claude Bernard University
Hospital is a 950-bed tertiary-care hospital with departments
in all medical and surgical specialties (except paediatrics, neu-
rosurgery and haematology), a 60-bed rehabilitation unit, and
a maternity ward with about 2500 deliveries per year; the
annual number of admissions for more than 24 h is approxi-
mately 35 000, with patients being hospitalized for a total of
approximately 270 000 hospital days. The Bretonneau Hospi-
tal is a geriatric university-afﬁliated hospital with 32 acute-
care beds, 68 intermediate-care beds and 105 extended-stay
beds; the annual number of admissions for more than 24 h is
approximately 1000, with 70 000 hospital days. A compre-
hensive strategy for controlling MRSA has been developed
subsequent to the early 1990s, including screening in the
intensive care units (ICUs) and high-risk units, and contact
precautions for colonized patients [5].
Microbiological methods
S. aureus was identiﬁed using the coagulase test with rabbit
plasma and the DNAse (1997–2002) or slidex agglutination
test (2003–2007). Methicillin resistance was determined using
the disk-agar diffusion method with a 5-lg oxacillin disk incu-
bated for 24–48 h at 30C (1997–2003) or a 30-lg cefoxitin
disc incubated for 24 h at 37C (2004–2007), as recom-
mended by the French Society for Microbiology (http://
www.sfm.asso.fr). Susceptibilities to oﬂoxacin, gentamicin,
kanamycin, tobramycin, erythromycin, clindamycin, pristina-
mycin, tetracycline, rifampicin, fusidic acid, cotrimoxazole,
vancomycin and teicoplanin were tested routinely using the
disk-diffusion method. Isolates with intermediate susceptibil-
ity to an antibiotic were classiﬁed as resistant. The presence
of the mecA gene was determined in strains with a
20–21 mm oxacillin diameter or a 25–26 mm cefoxitin
diameter using conventional PCR [6] from 1997 to 2003 and
triplex real-time PCR thereafter [7].
We examined all MRSA-positive cultures from clinical
specimens (but not those from surveillance specimens) that
were entered in the laboratory database between 1 January
1997 and 31 December 2007. The information obtained
from the database comprised the date and source of the
MRSA-positive culture and patient age, gender and location
(outpatient clinic, medical ward, surgical ward, rehabilitation/
intermediate-care or extended-care ward, intensive care unit,
or gynaecology–maternity ward). MRSA strains isolated
within 2 days of hospital admission or at the outpatient clinic
were classiﬁed as imported cases and other strains as hospi-
tal onset.
We excluded duplicate MRSA isolates, deﬁned as isolates
that were from the same patient with a similar susceptibility
pattern for all the antibiotics tested (resistant or intermediate
categories results were considered identical) and that were
recovered during the same year. When several MRSA iso-
lates with different susceptibility patterns were obtained
from the same patient, one strain exhibiting each pattern
was included in the study. We computed the incidence of
MRSA as the number of nonduplicate MRSA isolates divided
by the number of admissions for more than 24 h during the
same year.
Prior to analysis, we distinguished four MRSA susceptibility
patterns based on susceptibility to aminoglycosides and ﬂuor-
oquinolones (oﬂoxacin): resistant to oﬂoxacin, gentamicin,
kanamycin and tobramycin (Pattern 1, P1); resistant to oﬂox-
acin, kanamycin and tobramycin but susceptible to gentamicin
(Pattern 2, P2); resistant to oﬂoxacin but susceptible to
kanamycin, gentamicin and tobramycin (Pattern 3, P3); and
susceptible to oﬂoxacin with variable susceptibility to amino-
glycosides (Pattern 4, P4) (Table 1). Only eight MRSA iso-
lates were resistant to oﬂoxacin and kanamycin but
susceptible to gentamicin and tobramycin; these isolates
were studied separately. During the analysis process, we dis-
tinguished additional patterns in P2 and P3, based on suscep-
tibility to erythromycin, to test the hypothesis of divergent
trends. Because the distribution of erythromycin susceptibil-
ity was stable over time in P2 and P3, this subclassiﬁcation
was not pursued.
Molecular typing
Among MRSA isolates recovered in 2005 and 2007, ten iso-
lates per year from each of the four susceptibility patterns
(except for P1 in 2007 because only nine isolates were cul-
tured) were chosen at random and subjected to multilocus
sequence typing (MLST) and spa typing, as described
previously.
Their SCCmec types were characterized by multiplex PCR
typing of ccr and mec complexes as described previously [8].
The SCCmec IV types were subtyped by a PCR-multiplex
targeting junkyard region J1 as described previously [8]. The
presence of lukSF-lukPV operon was detected by PCR as
described previously [9].
Statistical analysis
We looked for associations between each of the four sus-
ceptibility patterns and patient characteristics by comparing
one pattern with the other three patterns combined, using
the chi-square test and Student’s t-test. Continuous variables
were converted to categorical variables, and the relative
risks and 95% CIs were computed. p <0.05 or lower was
considered statistically signiﬁcant. Variables that were signiﬁ-
cant in the bivariate analysis were entered into a logistic
regression model using a stepwise forward selection procedure
1436 Clinical Microbiology and Infection, Volume 16 Number 9, September 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1435–1441
to identify factors that were signiﬁcantly associated with each
MRSA pattern. All analyses were performed using EpiInfo,
version 6 (CDC, Atlanta, GA, USA) and SPSS, version 15.0
for Windows (SPSS Inc, Chicago, IL, USA).
Results
We included 3446 MRSA isolates. The annual number of iso-
lates varied in the range 339–374 between 1997 and 2002
(incidence 1.00–1.12 per 100 admissions) then decreased,
reaching 212 in 2007 (incidence 0.62 in 2007; p <0.0001)
(Fig. 1).
The number of MRSA isolates exhibiting patterns 1 to 4
was 810, 1850, 532 and 254, respectively (Table 1). P1 pre-
dominated in 1997 (183 isolates; incidence 0.60 per 100
admissions) but decreased thereafter, to only nine isolates in
2007 (Fig. 1). P2 became the predominant pattern in 1998,
remained stable until 2004 (159 to 189 isolates; incidence
0.50–0.63 per 100 admissions), and decreased thereafter
(107 isolates in 2007; incidence, 0.31 per 100 admissions). P3
increased steadily, from 13 isolates in 1997 to 72 in 2007. P4
remained stable over time, with 14–31 isolates per year.
Variables independently associated with the P1 susceptibil-
ity pattern were year of collection [adjusted OR (aOR)
0.75], male gender (aOR 1.54), age higher than 80 years
(aOR 0.77), hospital onset (aOR 1.44), being hospitalized in
the intensive care unit (aOR 3.25) and being hospitalized in
non-acute care wards (aOR 0.40). P2 was independently
associated with year of collection (aOR 1.04), male gender
(aOR 0.78), age under 40 years (aOR 0.46) and being hospi-
talized in the intensive care unit (aOR 0.51). P3 was indepen-
dently associated with year of collection (aOR 1.24), age
under 40 years (aOR 0.55) or higher than 80 years (aOR
1.90) and being hospitalized in the intensive care unit
(aOR 0.55) or in an intermediate or long-term care ward
(aOR 1.92). Finally, P4 was independently associated with
TABLE 1. Demographic and epidemiological associations of 3438 methicillin-resistant Staphylococcus aureus (MRSA) isolates
from patients with MRSA colonization or infection, according to susceptibility patterns, Bichat–Claude Bernard and Breton-
neau Hospitals, 1997–2007
Pattern 1
(n = 810)
Pattern 2
(n = 1850)
Pattern 3
(n = 532)
Pattern 4
(n = 246)
All patterns
(n = 3438)
Resistant K, T, G, Fq K, T, Fq Fq
Susceptible G K, T, G Fq
Age, years (mean ± SD) 65.4 ± 17.5 69.9 ± 17.7 75.0 ± 17.1 51.2 ± 23.6 68.2 ± 18.9
Age [n, (%)]
<40 years 87 (10.7) 122 (6.6) 24 (4.5) 93 (36.6) 326 (9.5)
40–80 years 561 (69.3) 1126 (60.9) 248 (46.6) 132 (52.0) 2067 (60.0)
> 80 years 162 (20.0) 602 (32.5) 260 (48.9) 29 (11.4) 1053 (30.6)
Male gender [n, (%)] 528 (65.2) 956 (51.7) 274 (51.5) 130 (52.8) 1894 (55.0)
Department [n, (%)]
Medicine 306 (37.8) 915 (49.5) 258 (48.5) 116 (44.3) 1595 (46.3)
Surgery 172 (21.2) 447 (24.2) 102 (19.2) 73 (29.3) 794 (23.0)
Intensive care unit 298 (36.8) 230 (12.4) 40 (7.5) 21 (8.5) 589 (17.1)
Obstetrics-Gynaecology 5 (0.6) 43 (2.3) 10 (1.9) 34 (13.8) 92 (2.7)
Rehab/intermediate or long-term care 29 (3.6) 215 (11.6) 122 (22.9) 10 (4.1) 376 (10.9)
Specimen [n, (%)]
Blood 45 (5.6) 88 (4.8) 19 (3.6) 11 (4.5) 163 (4.7)
Tracheal secretion 112 (13.8) 221 (11.9) 67 (12.6) 23 (9.4) 423 (12.3)
Urine 86 (10.6) 292 (15.8) 106 (19.9) 7 (2.8) 491 (14.3)
Catheter 77 (9.6) 51 (2.8) 12 (2.2) 3 (1.2) 143 (4.2)
Wound 262 (32.3) 821(44.3) 238 (44.7) 126 (51.2) 1447 (42.1)
Other 228 (28.1) 377 (20.4) 90 (17.0) 76 (30.9) 771 (22.4)
Acquisition [n, (%)]
Imported cases 223 (27.5) 658 (35.6) 185 (34.8) 145 (56.5) 1211 (35.1)
Hospital onset 587 (72.5) 1192 (64.4) 347 (65.2) 109 (43.5) 2235 (64.9)
Eight MRSA strains with other susceptibility patterns (i.e. intermediate susceptibility or resistance to oﬂoxacin and kanamycin) were excluded.
K, kanamycin; T, tobramycin; G, gentamicin; Fq, ﬂuoroquinolones.
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FIG. 1 Evolution of incidence of methicillin-resistant Staphylococcus
aureus per 100 admissions from 1997 to 2007, globally and according
to susceptibility patterns from 1997–2007.
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year of collection (aOR 1.10), age under 40 years (aOR
4.46) or higher than 80 years (aOR 0.40), hospital onset
(aOR 0.51) and being hospitalized in the intensive care unit
(aOR 0.54) or in the gynaecology–obstetrics ward (adjusted
OR 1.88) (Table 2).
Molecular typing of the 79 isolates selected at random in
2005 and 2007 (Table 3) showed that isolates exhibiting P1,
P2 and P3 were mainly clonal, based on MLST and SCCmec
results. Most P1 isolates (14/19; 74%) were ST 247-SCCmecI
(Iberian clone) [10]. Isolates with the P2 pattern were mostly
clonal, with 17 of 20 (85%) of them being ST8-IVc (Lyon
clone); furthermore, 16 of these 17 isolates had the same
spa-type, t008. P3 contained two major clones, ST8-IVc (9/
20; 45%) and ST5-VI (8/20; 40%). Eight of the ST8-IVc strains
TABLE 2. Multivariate analysis of variables associated with four susceptibility patterns of Methicillin-resistant Staphylococcus
aureus isolates recovered at the Bichat–Claude Bernard and Bretonneau Hospitals, 1997–2007
Adjusted OR (95% CI), p Pattern 1 Pattern 2 Pattern 3 Pattern 4
Year (by year) 0.75 (0.72–0.78)
<0.0001
1.04 (1.02–1.06)
0.001
1.24 (1.20–1.28)
<0.0001
1.10 (1.05–1.15)
<0.001
Male gender 1.54 (1.28–1.85)
<0.0001
0.78 (0.68–0.89)
<0.0001
– –
Age
<40 years – 0.46 (0.37–0.59)
<0.0001
0.55 (0.35–0.86)
0.008
4.46 (3.18–6.27)
<0.0001
> 80 years 0.77 (0.65–0.90)
0.002
– 1.90 (1.53–2.36)
<0.0001
0.40 (0.27–0.61)
<0.0001
Hospital onset 1.43 (1.18–1.74)
<0.0001
– – 0.51 (0.38–0.70)
<0.0001
Ward
Intensive care unit 3.25 (2.64–4.00)
<0.0001
0.51 (0.42–0.61)
<0.0001
0.55 (0.39–0.79)
0.001
0.54 (0.33–0.86)
0.01
Obstetrics–gynaecology – – – 1.88 (1.12–3.17)
0.017
Rehab/intermediate or long-term care 0.40 (0.26–0.61)
<0.0001
– 1.92 (1.47–2.52)
<0.0001
–
Each susceptibility pattern was compared with the three other patterns combined.
Pattern 1, resistant to kanamycin, tobramycin, gentamicin, and ﬂuoroquinolones; Pattern 2, resistant to kanamycin, tobramycin, and ﬂuoroquinolones but susceptible to genta-
micin; Pattern 3, resistant to ﬂuoroquinolones but susceptible to kanamycin, tobramycin, and gentamicin; Pattern 4, susceptible to ﬂuoroquinolones.
TABLE 3. Typing (MLST, SCCmec type, spa type, and presence of PVL gene) of ten randomly selected isolates in 2005 and
2007 (except nine for P1 in 2007) exhibiting each of the four patterns
Pattern n MLST CC SCCmec type spa-type PVL
P1 14 247 8 I t844 (n = 7), t052 (n = 4),
t2293 (n = 2), t024 (n = 1)
)
1 111 228 I t041 )
1 642 30 I t018 )
1 239 8 III t421 )
2 8 8 IVc t3291, t008 )
P2 17 8 8 IVc t008 (n = 16), t190 (n = 1) )
1 1237 (8 SLV pta) 8 IVc t008 )
1 1238 (8 SLV arcC) 8 IVc t008 )
1 5 5 IVc t002 )
P3 9 8 8 IVc t008 (n = 8), t430 (n = 1) )
1 1239 (8 SLV gmk) 8 IVc t008 )
8 5 5 VI t777 )
1 45 45 IVd t038 )
1 22 22 IVnt t032 )
P4 7 80 80 IVc t044 +
3 5 5 IVc t002 )
2 5 5 V t688 )
1 5 5 IVa t1277 )
1 5 5 VI t777 )
2 8 8 IVc t008, t304 )
1 8 8 V t008 )
1 45 45 IVb t105 )
1 45 45 IVc t044 )
1 22 22 IVnt t756 )
MLST, multilocus sequence typing; CC, clonal complex; PVL, Panton–Valentine leucocidin; nt, non typable.
Pattern 1, resistant to kanamycin, tobramycin, gentamicin, and ﬂuoroquinolones; Pattern 2, resistant to kanamycin, tobramycin, and ﬂuoroquinolones but susceptible to genta-
micin; Pattern 3, resistant to ﬂuoroquinolones but susceptible to kanamycin, tobramycin, and gentamicin; Pattern 4, resistant to kanamycin, tobramycin, and gentamicin but
susceptible to ﬂuoroquinolones.
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were spa type t008 and all ST5-VI were spa type t777, desig-
nated the ‘new’ Paediatric clone [11]. P4 isolates were more
diverse, including ten different combinations of ST and
SCCmec types. Interestingly, the most prevalent clone (7/20;
35%) of the P4 group was PVL positive ST80-IVc-t044 (the
community-associated ‘European MRSA clone’). These seven
isolates were only resistant to kanamycin, tetracycline, eryth-
romycin and fusidic acid.
Among the 254 P4-MRSA isolates recovered over the
11-year study period, 36 (14.2%) displayed the ST80-PVL-
positive susceptibility pattern of the community-associated
‘European MRSA clone’, with resistance or intermediate
susceptibility to kanamycin, tetracycline and fusidic acid. The
frequency of this pattern increased from nine isolates during
the whole of the ﬁrst 6 years (1997–2002) to eight isolates
in 2007 alone.
Eight of the 3446 isolates were resistant to oﬂoxacin and
kanamycin but susceptible to gentamicin and tobramycin and
were not classiﬁed in the four patterns; six out of eight were
imported cases. Two of these isolates were from skin
abscesses in teenagers who had been in close contact with
US citizens at a summer camp. These isolates were deﬁned
as the USA300 clone by the French National Reference Cen-
ter for Staphylococci (PVL gene, agr-1, ST8, SCCmec IVa,
t008 spa type and the presence of the ACME-element).
Discussion
The epidemiology of MRSA changed rapidly from 1997 to
2007 in two hospitals located in the same Paris neighbour-
hood. More speciﬁcally, the overall incidence of MRSA
decreased over the last 5 years of the study and phenotypi-
cally-deﬁned resistant isolates were replaced by isolates
exhibiting greater susceptibility. We identiﬁed a number of
patient characteristics that were independently associated
with the MRSA susceptibility pattern.
The decreasing incidence of MRSA over the last 5 years is
in agreement with French national surveillance data [12]. This
overall decrease has been accompanied by profound changes
in MRSA epidemiology, as revealed by our data on susceptibil-
ity patterns and molecular types. One cause of the decrease in
MRSA incidence may be the sharp decrease in the gentamicin-
resistant SCCmec I MRSA pattern (P1), as described previously
[3,4]. In our study hospitals, this pattern has almost completely
disappeared. Patterns 2 and 3, both susceptible to gentamicin,
differed in their susceptibility to kanamycin and tobramycin;
their overall incidence remained stable over time, with a
decrease in P2 being balanced by an increase in P3. Most of the
P2 and half of the P3 MRSA isolates during 2005 and 2007
belonged to the same ST8-IVc, t008 clone, known as the Lyon
clone, which is the predominant hospital-associated MRSA
clone in France [11]. Approximately half of the P3 isolates
may have derived from P2 strains by loss of the aadD gene for
tobramycin resistance.
The emergence of ST5-VI t777 clone, called the ‘new’ Pae-
diatric clone [11] may partly explain the increasing incidence
of P3.
The reasons why some clones supplant others are
unknown. The decreasing use of aminoglycosides may be
responsible for the decline in P1 MRSA isolates in France
[4]. Other antibiotics, however, exert selective pressure on
resistant strains, which would be expected to promote
the emergence of MRSA strains with greater (and not less)
resistance. The competitive ﬁtness advantage, demonstrated
in vitro, of gentamicin-susceptible MRSA strains over resistant
ones has been proposed to explain this replacement [13]. In
addition, MRSA isolates from the predominant ST8-IVc, t008
clone, carry a pathogenicity island that may be involved in
dissemination and infectivity [14]. However, the infection
control strategy started in the early 1990s in the ICUs may
have contributed to the decrease of P1 MRSA isolates.
We found that MRSA susceptibility patterns were associ-
ated with several patient characteristics. The gentamicin-
resistant P1 was associated with male gender, hospital onset
and ICU admission, independently of the year of collection
[15]. P3 was associated with older age and admission to
extended-care wards. Data from national and international
surveillance networks provide evidence that the epidemiol-
ogy of MRSA is changing both locally and regionally, with dis-
semination of MRSA in speciﬁc patient populations and
hospital departments. The results obtained in the present
study indicate that MRSA dissemination is inﬂuenced by
epidemiological and microbiological factors, whose mecha-
nisms of action remain poorly understood [16]. However,
the association of a particular pattern with epidemiological
characteristics does not necessarily translate into causal link
because of possible confounding factors such as concurrent
outbreaks. Other studies have shown that some MRSA
strains may have a greater tendency to induce outbreaks
than others (e.g. EMRSA-15 and -16) [15,17,18]. Information
of epidemiological importance could be obtained by analysing
clinical data from patients with different MRSA susceptibility
patterns.
The incidence of the oﬂoxacin-susceptible P4 was stable
over time, with approximately 20–40 isolates every year.
We selected this susceptibility pattern to detect commu-
nity-associated MRSA strains, as reported previously [19].
P4 was associated with younger age, community onset and
admission to the gynaecology–obstetrics ward, independently
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of the year of collection. These epidemiological characteris-
tics are those of community-acquired MRSA. However, of
the 20 P4 isolates subjected to molecular typing, only
seven belonged to the predominant European CA-MRSA
ST80-IVc clone [20]; the 13 other isolates were distributed
among other genotypic backgrounds. Additional data would
help to delineate this heterogeneous pattern. The associa-
tion of P4 with year of collection was chieﬂy ascribable to
the decreasing incidence of other patterns because the
crude number of isolates remained stable over time. The
results obtained in the present study suggest that commu-
nity-associated MRSA may exist at a low frequency in hos-
pitals in the Paris area.
However, susceptibility to oﬂoxacin is not the exclusive
criterion of community-associated MRSA; indeed, eight
isolates resistant to ﬂuoroquinolones, but not classiﬁed in
one pattern, were also mainly imported cases. Two of
them were responsible for severe skin and soft tissue
infections that required surgical debridement and antimi-
crobial treatment. Both were USA300, according to molec-
ular analysis, and occurred in patients who had recently
been in contact with an infected individual in the USA. In
our experience, MRSA USA300 remains extremely rare in
France.
Although the present study covers a long period and
provides detailed epidemiological data, it has several limita-
tions. First, the data from the two study centres may not
apply to regions in France outside Paris. Furthermore, the
results obtained in the present study suggest that local epi-
demiological conditions play a crucial role in the dissemina-
tion of a particular clone. Second, the change of our MRSA
detection method from 5 lg oxacillin to 30 lg cefoxitin
disk in the middle of the study may have affected the
results because the 5 lg oxacillin disk method has been
reported to under-detect gentamicin susceptible MRSA
[21]. Third, we compared isolates having one susceptibility
pattern with those having the other three patterns com-
bined. This method identiﬁes variables that mirror one
another and ampliﬁes differences between patterns. Never-
theless, our statistical analysis showed that the different
patterns had different epidemiological characteristics. Finally,
molecular analysis was performed only on a limited subset
of MRSA isolates from 2005 and 2007 because older iso-
lates were no longer available. We cannot be sure that the
results from these 2 years reﬂect the characteristics over
the entire 11-year period.
In conclusion, the results obtained in the present study
indicate the need for local evaluations of MRSA epidemiology
in addition to studies of global trends. Phenotypically-deﬁned
clones are supplanted by others over the years, varying with
patient characteristics and environmental settings. Combining
epidemiological studies of MRSA exhibiting different suscepti-
bility patterns with the molecular analysis of selected isolates
may help our understanding of the epidemiology of hospital-
associated MRSA.
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